These findings were confirmed following in vivo WASp reconstitution in WAS patients treated with clinical gene therapy, where rapamycin stimulation of MDMs from WAS patients treated with gene therapy demonstrated LC3 punctae formation comparable to healthy controls (Figure 1g and h). This evidence concerns the gene MAP1LC3A and Wiskott-Aldrich syndrome.